{"id":"ino","safety":{"commonSideEffects":[{"rate":null,"effect":"Methemoglobinemia"},{"rate":null,"effect":"Nitrogen dioxide formation"},{"rate":null,"effect":"Rebound hypoxemia upon discontinuation"}]},"_chembl":null,"_dailymed":{"setId":"cc7014b1-c775-411d-b374-8113248b4077","title":"BESPONSA (INOTUZUMAB OZOGAMICIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [WYETH PHARMACEUTICALS LLC, A SUBSIDIARY OF PFIZER INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nitric oxide is a potent selective pulmonary vasodilator that reduces pulmonary vascular resistance and improves ventilation-perfusion matching in the lungs. By preferentially dilating vessels in well-ventilated lung regions, iNO enhances oxygen uptake and reduces intrapulmonary shunting, thereby improving arterial oxygenation in critically ill patients.","oneSentence":"iNO is inhaled nitric oxide gas that dilates pulmonary blood vessels and improves oxygenation in patients with severe respiratory failure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:08.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute respiratory distress syndrome (ARDS)"},{"name":"Persistent pulmonary hypertension of the newborn (PPHN)"},{"name":"Hypoxic respiratory failure"}]},"trialDetails":[{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT05748171","phase":"PHASE2","title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-05-17","conditions":"ACUTE LYMPHOBLASTIC LEUKEMIA","enrollment":100},{"nctId":"NCT04996667","phase":"PHASE2","title":"Effect of iNO in Patients With Submassive and Massive PE","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2026-06-01","conditions":"Pulmonary Embolism, Pulmonary Embolism Subacute Massive","enrollment":""},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT07474051","phase":"","title":"Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials","status":"ENROLLING_BY_INVITATION","sponsor":"AvenCell Therapeutics, Inc.","startDate":"2026-01-29","conditions":"B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy","enrollment":178},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT07431840","phase":"NA","title":"Immune Defense Protein Impact On Respiratory Immune Outcomes","status":"RECRUITING","sponsor":"Quantec Ltd","startDate":"2025-12-05","conditions":"Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection","enrollment":300},{"nctId":"NCT02836899","phase":"PHASE3","title":"Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-02-08","conditions":"Acute Kidney Injury","enrollment":250},{"nctId":"NCT07443488","phase":"PHASE2","title":"Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-14","conditions":"HSCT, Ph+ ALL","enrollment":20},{"nctId":"NCT04367675","phase":"PHASE1","title":"INO 5401 Vaccination in BRCA1/2 Mutation Carriers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2021-04-20","conditions":"BRCA1/2 Mutation","enrollment":44},{"nctId":"NCT07193407","phase":"NA","title":"INOPASE - Performance and Safety Study of a Personalised SNM System","status":"RECRUITING","sponsor":"INOPASE Pty Ltd","startDate":"2026-02-27","conditions":"Overactive Bladder (OAB)","enrollment":10},{"nctId":"NCT03913559","phase":"PHASE2","title":"Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-05-14","conditions":"Acute Lymphoblastic Leukemia","enrollment":5},{"nctId":"NCT05213676","phase":"PHASE4","title":"De-implementing Inhaled Nitric Oxide for Congenital Diaphragmatic Hernia","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-11-01","conditions":"Congenital Diaphragmatic Hernia","enrollment":600},{"nctId":"NCT07382258","phase":"NA","title":"A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Novlead Inc.","startDate":"2023-05-17","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":16},{"nctId":"NCT01172691","phase":"PHASE2","title":"Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2010-07","conditions":"Liver Transplant","enrollment":23},{"nctId":"NCT06444477","phase":"","title":"Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2024-08-13","conditions":"Immune Thrombocytopenia, Immune Thrombocytopenic Purpura, Neoplasms","enrollment":33},{"nctId":"NCT04230265","phase":"PHASE1","title":"Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies","status":"TERMINATED","sponsor":"AvenCell Europe GmbH","startDate":"2020-01-28","conditions":"Acute Myeloid Leukemia (AML)","enrollment":32},{"nctId":"NCT07334873","phase":"NA","title":"Effect of Inhaled Nitric Oxide Therapy in Adults With Moderate-to-Severe Acute Respiratory Distress Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-01","conditions":"ARDS (Moderate or Severe)","enrollment":536},{"nctId":"NCT05456698","phase":"PHASE2","title":"Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-10-18","conditions":"Acute Lymphocytic Leukemia","enrollment":31},{"nctId":"NCT07297264","phase":"PHASE3","title":"Betamethasone and Complications of Lower Third Molar Surgery","status":"TERMINATED","sponsor":"Shehab Ahmed Hamad","startDate":"2022-01-03","conditions":"Morbidity, Third Molars Extraction, Steroid Injection","enrollment":40},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT07265518","phase":"NA","title":"Outpatient Induction of Labour Using a Double Balloon Transcervical Catheter in Low-risk Pregnant Women: a Two-centre Open Prospective Randomised Controlled Trial - OutCRIB","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2025-12-15","conditions":"Pregnant Women","enrollment":258},{"nctId":"NCT03748082","phase":"PHASE2","title":"Effects of Nitric Oxide on the Endothelium During Hemolysis.","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2018-12-05","conditions":"Endothelial Dysfunction, Hemolysis Intravascular, Cardiovascular Diseases","enrollment":""},{"nctId":"NCT04022161","phase":"PHASE2","title":"Effects of Prolonged Delivery of Nitric Oxide Gas on Plasma Reduction-Oxidation Reactions in Cardiac Surgical Patients","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-07-25","conditions":"Cardiovascular Diseases, Oxidative Stress, Endothelial Dysfunction","enrollment":""},{"nctId":"NCT07252869","phase":"","title":"Evaluation of Impression Accuracy: Digital Scanner Versus Analog Technique","status":"COMPLETED","sponsor":"University of Milan","startDate":"2017-07-15","conditions":"Accuracy and Precision of Noninvasive Measurement","enrollment":51},{"nctId":"NCT07238907","phase":"","title":"A Multi-center Retrospective Study of INO Treating B-ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-06-01","conditions":"Acute Lymphoblastic Leukaemia, Acute Lymphoblastic Leukaemias (ALL), Inotuzumab Ozogamicin","enrollment":102},{"nctId":"NCT07247240","phase":"PHASE4","title":"Efficacy of Inhaled Nitric Oxide in Congenital Diaphragmatic Hernia","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-11","conditions":"Congenital Diaphragmatic Hernia, Pulmonary Hypertension","enrollment":40},{"nctId":"NCT05871606","phase":"PHASE1","title":"Inhaled Nitric Oxide in Acute Ischemic Stroke Patients Undergoing Mechanical Thrombectomy","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2025-11-11","conditions":"Cerebrovascular Disorders, Acute Cerebrovascular Disease","enrollment":36},{"nctId":"NCT05940961","phase":"PHASE2","title":"Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL","status":"RECRUITING","sponsor":"Sheng-Li Xue, MD","startDate":"2022-08-01","conditions":"ALL, MRD-positive, Hematopoietic Stem Cell Transplantation","enrollment":42},{"nctId":"NCT07170475","phase":"PHASE1","title":"A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease","status":"RECRUITING","sponsor":"Fujita Health University","startDate":"2025-06-27","conditions":"Parkinson's Disease (PD)","enrollment":24},{"nctId":"NCT07030543","phase":"NA","title":"Feasibility Of Individualized Dietary Plan (Idp) On Glycemic Control And Total Cholestrol In Diabetic Patients At Diabetes Hospital And Research Centre Peshawar","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2025-02-01","conditions":"Type 2 Diabetes Mellitus","enrollment":122},{"nctId":"NCT03023449","phase":"PHASE2","title":"Diffuse Optical Monitoring With Inhaled Nitric Oxide","status":"ACTIVE_NOT_RECRUITING","sponsor":"Steven Messe","startDate":"2017-04-04","conditions":"Stroke","enrollment":40},{"nctId":"NCT05935787","phase":"PHASE3","title":"Cytoflavin in the Complex Rehabilitation of Stroke Patients","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2023-06-09","conditions":"Stroke","enrollment":240},{"nctId":"NCT07125443","phase":"NA","title":"Effect Inhaled Nitric Oxide in Adult Liver Transplant","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2025-09-01","conditions":"Liver Diseases, Reperfusion Injury, Vasoplegia","enrollment":260},{"nctId":"NCT06355024","phase":"PHASE2","title":"Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2024-05-11","conditions":"Triple-negative Breast Cancer","enrollment":10},{"nctId":"NCT07059910","phase":"","title":"Prevalence of Thyroid Disorders in Patients With Immune Thrombocytopenic Purpura and Its Impact on Treatment","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-07","conditions":"Immune Thrombocytopenic Purpura, Thyroid Disorders","enrollment":100},{"nctId":"NCT06702553","phase":"PHASE3","title":"Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-05-19","conditions":"Nitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass","enrollment":3650},{"nctId":"NCT06744777","phase":"PHASE3","title":"The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever","status":"COMPLETED","sponsor":"Khyber Medical University Peshawar","startDate":"2024-12-17","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Severe Dengue","enrollment":284},{"nctId":"NCT05780099","phase":"","title":"Prospective Observational Study to Characterize Patients Treated at Internal Medicine Clinics","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2022-06-24","conditions":"Respiratory Disease, Cardiovascular Diseases, Infectious Disease","enrollment":50000},{"nctId":"NCT05896800","phase":"NA","title":"A Clinical Study of Inhaled Nitric Oxide in Moderate-to-Severe Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-06-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT05616910","phase":"PHASE2","title":"Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury","status":"ENROLLING_BY_INVITATION","sponsor":"University of Pennsylvania","startDate":"2025-04-06","conditions":"Traumatic Brain Injury","enrollment":38},{"nctId":"NCT05104606","phase":"NA","title":"Speckle Tracking and Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-11-02","conditions":"ARDS, Right Ventricle","enrollment":64},{"nctId":"NCT05801224","phase":"NA","title":"Vascular ARDS Recruitment After Inhaled Nitric Oxide","status":"SUSPENDED","sponsor":"Massachusetts General Hospital","startDate":"2026-07-01","conditions":"Acute Respiratory Distress Syndrome, Ventilation Perfusion Mismatch","enrollment":70},{"nctId":"NCT06183242","phase":"PHASE2, PHASE3","title":"Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2023-05-27","conditions":"Cholestasis, Intrahepatic","enrollment":328},{"nctId":"NCT05787366","phase":"NA","title":"Effect of a Health Pathway for People With Persistent Symptoms Covid-19","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-11-15","conditions":"COVID-19","enrollment":400},{"nctId":"NCT05928286","phase":"","title":"Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice","status":"RECRUITING","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2022-12-01","conditions":"Gallstone Disease, Obstructive Jaundice","enrollment":286},{"nctId":"NCT04631484","phase":"PHASE3","title":"International Trial of Efficacy of Cytoflavin in Head Trauma","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2020-11-22","conditions":"Head Trauma,Closed","enrollment":166},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT04747912","phase":"PHASE2","title":"Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2021-03-02","conditions":"Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia","enrollment":25},{"nctId":"NCT04228731","phase":"NA","title":"Inpatient vs Outpatient Total Knee Replacement","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2020-10-22","conditions":"Osteoarthritis, Knee","enrollment":123},{"nctId":"NCT06861348","phase":"PHASE2","title":"Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-03-01","conditions":"Leukemia, Lymphocytic, Acute","enrollment":23},{"nctId":"NCT06852924","phase":"NA","title":"Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE)","status":"RECRUITING","sponsor":"Novlead Inc.","startDate":"2023-08-10","conditions":"High Altitude Pulmonary Hypertension","enrollment":100},{"nctId":"NCT06832163","phase":"NA","title":"Close Loop Smart Weaning for INO With PPHN","status":"NOT_YET_RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-03-01","conditions":"Persistent Pulmonary Hypertension of the Newborn, Inhaled Nitric Oxide","enrollment":30},{"nctId":"NCT06675435","phase":"NA","title":"Inhaled Nitric Oxide in Severe Obesity","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-10","conditions":"Obesity, Respiratory Insufficiency, Hypoxemic Respiratory Failure","enrollment":60},{"nctId":"NCT05597085","phase":"","title":"A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-08","conditions":"Adult Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia","enrollment":32},{"nctId":"NCT03576885","phase":"PHASE1, PHASE2","title":"Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia","status":"TERMINATED","sponsor":"AdventHealth","startDate":"2019-07-15","conditions":"Pulmonary Hypertension, Bronchopulmonary Dysplasia","enrollment":32},{"nctId":"NCT05633147","phase":"PHASE1","title":"Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam","status":"COMPLETED","sponsor":"Cinclus Pharma Holding AB","startDate":"2022-11-27","conditions":"Safety Issues, Pharmacokinetics, Drug Interaction","enrollment":35},{"nctId":"NCT06444009","phase":"PHASE2","title":"A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Lei Liu","startDate":"2024-07-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT04114578","phase":"","title":"Exploratory Observational Prospective Study in Neonatal and Pediatric Congenital Diaphragmatic Hernia","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2019-10-01","conditions":"Congenital Diaphragmatic Hernia","enrollment":80},{"nctId":"NCT06650124","phase":"PHASE2, PHASE3","title":"Induction of Remission in Autoimmune Hepatitis With Azathioprine vs. MMF","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-11-01","conditions":"Autoimmune Hepatitis","enrollment":108},{"nctId":"NCT00515281","phase":"PHASE2, PHASE3","title":"Inhaled Nitric Oxide and Neuroprotection in Premature Infants","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2008-05","conditions":"Prematurity, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage","enrollment":273},{"nctId":"NCT02170519","phase":"PHASE4","title":"Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide","status":"TERMINATED","sponsor":"Duke University","startDate":"2006-09","conditions":"Pulmonary Hypertension","enrollment":27},{"nctId":"NCT04181359","phase":"PHASE1, PHASE2","title":"The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease.","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2024-09-01","conditions":"Dyspnea","enrollment":""},{"nctId":"NCT04231773","phase":"PHASE1, PHASE2","title":"The Effect of Inhaled Nitric Oxide on Maximal Oxygen Consumption During Exercise in Hypoxia","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2020-08-17","conditions":"Hypoxia","enrollment":20},{"nctId":"NCT06554626","phase":"PHASE2","title":"Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-08-15","conditions":"Precursor B-Cell Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT06533124","phase":"NA","title":"Parameters of Cardiac Indices on the Ultrasonic Cardiac Output Monitor As Potential Indicators for Predicting the Achievement of Ultrafiltration Endpoint for Acute Heart Failure Treatment","status":"COMPLETED","sponsor":"Shanghai Tong Ren Hospital","startDate":"2022-01-05","conditions":"Acute Heart Failure","enrollment":40},{"nctId":"NCT03439085","phase":"PHASE2","title":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-11-14","conditions":"Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm","enrollment":41},{"nctId":"NCT04633148","phase":"PHASE1","title":"Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker","status":"TERMINATED","sponsor":"AvenCell Europe GmbH","startDate":"2020-11-23","conditions":"Prostate Cancer","enrollment":16},{"nctId":"NCT06025682","phase":"","title":"Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO","status":"RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2024-04-04","conditions":"Acute Lymphoblastic Leukemia, Infections, Bacterial Infections","enrollment":158},{"nctId":"NCT04069052","phase":"EARLY_PHASE1","title":"The Effect of Inhaled Nitric Oxide on Deadspace in COPD","status":"COMPLETED","sponsor":"Dr. Denis O'Donnell","startDate":"2021-09-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":13},{"nctId":"NCT05052229","phase":"EARLY_PHASE1","title":"Inhaled Nitric Oxide (iNO) in Idiopathic Pulmonary Fibrosis (IPF).","status":"RECRUITING","sponsor":"Dr. Denis O'Donnell","startDate":"2022-04-21","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":40},{"nctId":"NCT04920695","phase":"NA","title":"Inhaled Nitric Oxide (iNO) in Post-Pulmonary Embolism (Post-PE)","status":"COMPLETED","sponsor":"Dr. Denis O'Donnell","startDate":"2021-05-14","conditions":"Dyspnea, Pulmonary Embolism","enrollment":16},{"nctId":"NCT06319235","phase":"PHASE1, PHASE2","title":"Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®","status":"RECRUITING","sponsor":"MB PHARMA s.r.o.","startDate":"2023-10-27","conditions":"Surgical Site Infection, Staphylococcus Aureus Infection, Pseudomonas Aeruginosa Infection","enrollment":52},{"nctId":"NCT06097026","phase":"NA","title":"Role of Inhaled Nitric Oxide in Vascular Mechanics and Right Ventricular Function","status":"UNKNOWN","sponsor":"Fernando Suarez Sipmann","startDate":"2023-11-22","conditions":"Collapsed Lung, Hemodynamic Stability","enrollment":54},{"nctId":"NCT03886519","phase":"NA","title":"Repeat Surgery for Patients With Post-operative Trachomatous Trichiasis Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2019-04-13","conditions":"Trichiasis, Surgery","enrollment":886},{"nctId":"NCT05867914","phase":"NA","title":"Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Third Pole Therapeutics, Inc.","startDate":"2023-12-04","conditions":"Hypertension, Pulmonary, Lung Diseases, Interstitial","enrollment":5},{"nctId":"NCT03831503","phase":"PHASE1","title":"A Study of INO-A002 in Healthy Dengue Virus-naive Adults","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2019-02-07","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT05868109","phase":"PHASE2","title":"Inhaled Nitric Oxide for Cardiac Arrest in Pediatrics and Adults (iNOCAPA)","status":"UNKNOWN","sponsor":"The Hospital for Sick Children","startDate":"2022-08-31","conditions":"Cardiac Arrest","enrollment":40},{"nctId":"NCT04476238","phase":"NA","title":"Inosine Energy Expenditure Study","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2022-02-28","conditions":"Healthy Volunteers","enrollment":8},{"nctId":"NCT06043635","phase":"","title":"Predictors of Inhaled Nitric Oxide Responsiveness in Patients With PPHN","status":"WITHDRAWN","sponsor":"Nationwide Children's Hospital","startDate":"2021-07-15","conditions":"PPHN, Hypoxic Respiratory Failure","enrollment":""},{"nctId":"NCT03249870","phase":"PHASE2","title":"Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL","status":"UNKNOWN","sponsor":"Versailles Hospital","startDate":"2017-12-28","conditions":"Acute Lymphoblastic Leukemia (ALL) - Philadelphia Chromosome (Ph)-Negative CD22+ B-cell Precursor (BCP)","enrollment":130},{"nctId":"NCT03267108","phase":"PHASE3","title":"A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension","status":"TERMINATED","sponsor":"Bellerophon Pulse Technologies","startDate":"2020-12-14","conditions":"Pulmonary Fibrosis, Pulmonary Hypertension","enrollment":145},{"nctId":"NCT05202938","phase":"","title":"eMESH Struct. 2022-23","status":"UNKNOWN","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2022-07-21","conditions":"Septic Shock, Chronic Heart Failure","enrollment":32},{"nctId":"NCT03991884","phase":"PHASE1","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2019-09-24","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT03538262","phase":"","title":"Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-10-01","conditions":"Parkinson Disease","enrollment":226},{"nctId":"NCT00945529","phase":"PHASE2, PHASE3","title":"The Effects of Inhaled Nitric Oxide After Fontan Operation","status":"COMPLETED","sponsor":"Ellen Spurrier","startDate":"2008-02","conditions":"Congenital Heart Defect","enrollment":21},{"nctId":"NCT05785195","phase":"NA","title":"A Mechanistic Study of Inhaled Nitric Oxide in COPD","status":"UNKNOWN","sponsor":"Ting YANG","startDate":"2023-03-14","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension","enrollment":15},{"nctId":"NCT05809336","phase":"PHASE2, PHASE3","title":"Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2019-05-01","conditions":"Advanced Solid Tumor","enrollment":172},{"nctId":"NCT05297851","phase":"","title":"Cytoflavin in Combination With Reperfusion in Stroke Patients","status":"COMPLETED","sponsor":"POLYSAN Scientific & Technological Pharmaceutical Company","startDate":"2022-04-10","conditions":"Acute Stroke","enrollment":200},{"nctId":"NCT05747508","phase":"PHASE2","title":"A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis","status":"UNKNOWN","sponsor":"Bellerophon","startDate":"2017-12-29","conditions":"Pulmonary Fibrosis, Pulmonary Hypertension","enrollment":85},{"nctId":"NCT01457781","phase":"PHASE2","title":"Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","sponsor":"Bellerophon Pulse Technologies","startDate":"2012-04","conditions":"Pulmonary Arterial Hypertension, Pulmonary Hypertension","enrollment":80},{"nctId":"NCT01728220","phase":"PHASE2","title":"Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD","status":"COMPLETED","sponsor":"Bellerophon Pulse Technologies","startDate":"2012-12","conditions":"Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease","enrollment":159},{"nctId":"NCT03725397","phase":"NA","title":"Inpatient Versus Outpatient Foley Cervical Ripening Study","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-01-08","conditions":"Induced; Birth","enrollment":54},{"nctId":"NCT04358588","phase":"","title":"Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Bellerophon","startDate":"","conditions":"Coronavirus Infection, COVID-19, Pneumonia, Viral","enrollment":""},{"nctId":"NCT02267655","phase":"PHASE1","title":"3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF","status":"COMPLETED","sponsor":"Bellerophon","startDate":"2015-05","conditions":"Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis","enrollment":8},{"nctId":"NCT03135860","phase":"EARLY_PHASE1","title":"Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen","status":"TERMINATED","sponsor":"Bellerophon","startDate":"2016-10","conditions":"COPD, Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease","enrollment":7},{"nctId":"NCT03602781","phase":"PHASE3","title":"Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric","status":"WITHDRAWN","sponsor":"Bellerophon Pulse Technologies","startDate":"2018-08","conditions":"Pulmonary Arterial Hypertension","enrollment":""},{"nctId":"NCT04421508","phase":"PHASE3","title":"A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19","status":"TERMINATED","sponsor":"Bellerophon Pulse Technologies","startDate":"2020-07-12","conditions":"COVID-19, Coronavirus, Coronavirus Infection","enrollment":191}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"LEUKOPENIA"},{"count":3,"reaction":"RESPIRATORY FAILURE"},{"count":2,"reaction":"BLINDNESS"},{"count":2,"reaction":"CARDIAC ARREST"},{"count":2,"reaction":"COMPLETED SUICIDE"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"GAMMA-GLUTAMYLTRANSFERASE INCREASED"},{"count":2,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":2,"reaction":"INSOMNIA"},{"count":2,"reaction":"PLATELET COUNT DECREASED"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inhaled Nitrous Oxide","Inhaled Nitric Oxide","Inhaled nitric oxide."],"phase":"marketed","status":"active","brandName":"iNO","genericName":"iNO","companyName":"Wake Forest University Health Sciences","companyId":"wake-forest-university-health-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"iNO is inhaled nitric oxide gas that dilates pulmonary blood vessels and improves oxygenation in patients with severe respiratory failure. Used for Acute respiratory distress syndrome (ARDS), Persistent pulmonary hypertension of the newborn (PPHN), Hypoxic respiratory failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}